Interferon Alfacon1 is a Potent Inhibitor of SARS-Corona Virus in Cell-Based Models
ARMY MEDICAL RESEARCH INST OF INFECTIOUS DISEASES FORT DETRICK MD
Pagination or Media Count:
Preliminary data examining interferon alphacon1 treatment of SARS-CoV severe acute respiratory syndrome-corona virus-infected patients suggest this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection CPE assay, interferon alfacon1 inhibited the generation of CPE in a dose-dependent manner with an IC50 of 0.001 gml, a clinically achievable level. Furthermore, interferon alphacon1 also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alphacon1 against SARS-CoV suggests continued evaluation of interferon alphacon1 as a therapeutic treatment for patients infected with SARS-CoV.
- Anatomy and Physiology
- Medicine and Medical Research